Experts recommend fine-tuning of HIV treatment

	Tweet

How quickly an HIV patient’s immune system deteriorates may not affect the outcome of the illness, a study has found, and this could help change current guidelines for treatment of the disease.

There is no cure for the human immunodeficiency virus (HIV) that causes AIDS, but combinations of drugs can keep the virus from replicating and damaging the immune system.

Doctors normally do not start treatment until there is some evidence of damage to this system, measured by counting the number of immune cells, called CD4 T-cells.

In developed countries, HIV treatment usually begins when CD4 numbers drop below 350 cells per microlitre of blood.

Some treatment guidelines also recommend that therapy be started more quickly for people whose CD4 counts decline rapidly.

But the study, involving an international team of researchers, found that the pace of decline did not result in any substantial differences to the outcome of the illness.

“What we looked at was whether it matters how a person reached his current CD4 cell count, whether the CD4 count declined very quickly, or very slowly, and we found that the CD4 cell dynamics don’t provide additional information about the patient’s prognosis on top of the current CD4 cell count,” said Marcel Wolbers of the Hospital for Tropical Diseases in Ho Chi Minh City in Vietnam.

Wolbers, a biostatistician and one of the principal investigators of the study, and his colleagues examined records of 2,820 HIV patients from Australia, Canada and Europe with varying rates of CD4 declines.

They found no significant differences in their progression to AIDS or the number of deaths.

“The current rate of CD4 cell decline is neither a strong predictor of whether a person is progressing to AIDS or dies, nor does it predict future CD4 cell decline,” he said. “Therefore, it shouldn’t guide clinical decisions, in particular the decision whether to initiate (drug) therapy or not.

“A further implication of our study is that the patient’s CD4 cell count should be monitored regularly regardless of the prior rate of CD4 decline and that should be done according to current guidelines, i.e. every three to six months.”

The study was published in the latest issue of PLoS (Public Library of Science) Medicine. ‘

HONG KONG (Reuters)

RELATED STORIES:
Indiana University Scientist Works to Detach Protein that HIV Uses as Protective Shield   New HIV-vaccine tested on people   New Research Reveals How Protein Protects Cells From HIV Infection   AIDS Prevention Inspires Ways to Make Circumcisions Easier   Bill Gates injects $750 million into troubled AIDS fund   Having a Dog or Cat Helps Women Cope with HIV/AIDS   Saliva HIV test passes the grade   Caution Needed When Choosing Seizure Drugs for People with HIV/AIDS   Drug to Treat HIV in Children Shows Promise Via National Clinical Trial   Study in monkeys raises hope for HIV vaccines   Pathogenic Landscape Of HIV   Bali HIV scare fuels concern over tattoo safety

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]